Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders
Tóm tắt
Nesfatin-1 and ghrelin are the two recently discovered peptide hormones involved in the control of appetite. Besides its main appetite-control function, ghrelin also has anticonvulsant effects, while nesfatin-1 causes depolarization in the paraventricular nucleus (PVN). The aims of this study, therefore, were to investigate: (i) whether there are differences in the concentrations of nesfatin-1 and ghrelin in saliva and serum samples between eplilepsy patients and normal controls and (ii) whether salivary glands produce nesfatin-1. The study included a total of 73 subjects: 8 patients who were newly diagnosed with primary generalized seizures and had recently started antiepileptic drug therapy; 21 who had primary generalized seizures and were continuing with established antiepileptic drug therapy; 24 who had partial seizures (simple: n = 12 or complex: n = 12) and were continuing with established antiepileptic drug therapy; and 20 controls. Salivary gland tissue samples were analyzed for nesfatin-1 expression by immunochemistry and ELISA. Saliva and serum ghrelin levels were measured by ELISA and RIA, and nesfatin-1 levels by ELISA. Nesfatin-1 immunoreactivity was detected in the striated and interlobular parts of the salivary glands and the ducts. The nesfatin-1 level in the brain was around 12 times higher than in the salivary gland. Before antiepileptic treatment, both saliva and serum nesfatin-1 levels were around 160-fold higher in patients who are newly diagnosed with primary generalized epilepsy (PGE) than in controls; these levels decreased with treatment but remained about 10 times higher than the control values. Saliva and serum nesfatin-1 levels from patients with PGE and partial epilepsies who were continuing antiepileptic drugs were also 10-fold higher than control values. Serum and saliva ghrelin levels were significantly (twofold) lower in epileptic patients before treatment than in controls; they recovered somewhat with treatment but remained below the control values. These results suggest that the low ghrelin and especially the dramatically elevated nesfatin-1 levels might contribute to the pathophyisology of epilepsy. Therefore, serum and saliva ghrelin and especially the remarkably increased nesfatin-1 might be candidate biomarkers for the diagnosis of epilepsy and for monitoring the response to anti-epileptic treatment.
Tài liệu tham khảo
Beck H, Elger CE (2008) Epilepsy research: a window onto function to and dysfunction of the human brain. Dialogues Clin Neurosci 10:7–15
Pack A (2005) Effects of treatment on endocrine function in patients with epilepsy. Curr Treat Options Neurol 7:273–280. doi:10.1007/s11940-005-0037-8
Quigg MS (2002) Seizures and circadian rhythms. In: Bazil CW, Malow BA, Sammaritano MH (eds) Sleep and epilepsy: the clinical spectrum. Elsevier, The Netherlands, 31 pp
Meierkord H, Shorvon S, Lightman SL (1994) Plasma concentrations of prolactin, noradrenaline, vasopressin and oxytocin during and after a prolonged epileptic seizure. Acta Neurol Scand 90:73–77
Rosenfeld WE, Doose DR, Walker SA, Nayak RK (1997) Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 38:317–323. doi:10.1111/j.1528-1157.1997.tb01123.x
Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, Tsuchiya T, Monden T, Horiguchi K, Yamada M, Mori M (2006) Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 443:709–712. doi:10.1038/nature05162
Pan W, Hsuchou H, Kastin AJ (2007) Nesfatin-1 crosses the blood-brain barrier without saturation. Peptides 28:2223–2228. doi:10.1016/j.peptides.2007.09.005
Price TO, Samson WK, Niehoff ML, Banks WA (2007) Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides 28:2372–2381. doi:10.1016/j.peptides.2007.10.008
Kohno D, Nakata M, Maejima Y, Shimizu H, Sedbazar U, Yoshida N, Dezaki K, Onaka T, Mori M, Yada T (2008) Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology 149:1295–1301. doi:10.1210/en.2007-1276
Stengel A, Goebel M, Yakubov I, Wang L, Witcher D, Coskun T, Taché Y, Sachs G, Lambrecht NW (2009) Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 150:232–238. doi:10.1210/en.2008-0747
Price CJ, Hoyda TD, Samson WK, Ferguson AV (2008) Nesfatin-1 influences the excitability of paraventricular nucleus neurones. J Neuroendocrinol 20:245–250
Price CJ, Samson WK, Ferguson AV (2008) Nesfatin-1 inhibits NPY neurons in the arcuate nucleus. Brain Res 1230:99–106. doi:10.1016/j.brainres.2008.06.084
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660. doi:10.1038/45230
Aydin S (2007) Discovery of ghrelin hormone: research and clinical applications, Turk. J Biochem 32:76–89
Kojima M, Kangawa K (2005) Ghrelin: structure and function. Physiol Rev 85:495–522. doi:10.1152/physrev.00012.2004
Banks WA, Tschöp M, Robinson SM, Heiman ML (2002) Extent and direction of ghrelin transport across the blood–brain barrier is determined by its unique primary structure. J Pharmacol Exp Ther 302:822–827. doi:10.1124/jpet.102.034827
Obay BD, Tasdemir E, Tumer C, Bilgin HM, Sermet A (2007) Antiepileptic effects of ghrelin on pentylenetetrazole-induced seizures in rats. Peptides 28:1214–1219. doi:10.1016/j.peptides.2007.04.003
Berilgen MS, Mungen B, Ustundag B, Demir C (2006) Serum ghrelin levels are enhanced in patients with epilepsy. Seizure 15:106–111. doi:10.1016/j.seizure.2005.11.008
Greco R, Latini G, Chiarelli F, Iannetti P, Verrotti A (2005) Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology 65:1808–1809. doi:10.1212/01.wnl.0000187074.27586.d1
The Commission on Classification, Terminology of the International League Against Epilepsy (1981) Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 22:489–501. doi:10.1111/j.1528-1157.1981.tb06159.x
Hosoda H, Doi K, Nagaya N, Okumura H, Nakagawa E, Enomoto M, Ono F, Kangawa K (2004) Optimum collection and storage conditions for ghrelin measurements: octanoyl modification of ghrelin is rapidly hydrolyzed to desacyl ghrelin in blood samples. Clin Chem 50:1077–1080. doi:10.1373/clinchem.2003.025841
Hsu SM, Raine L, Fanger H (1981) Use of avidin–biotinperoxidasecomplex (ABC) in immunoperoxidase technique. J Histochem Cytochem 29:577–580
Aydin S, Halifeoglu İ, Ozercan İH, Erman F, Kilic N, Aydin S, Ilhan N, Ilhan N, Ozkan YN, Akpolat N, Sert L, Caylak E (2005) A comparison of leptin and ghrelin levels in plasma and saliva of young healthy subjects. Peptides 26:647–652. doi:10.1016/j.peptides.2004.11.008
Ozbay Y, Aydin S, Dagli AF, Akbulut M, Dagli N, Kilic N, Rahman A, Sahin İ, Polat V, Ozercan İH HI, Arslan N, Sensoy D (2008) Obestatin is present in saliva: alterations in obestatin and ghrelin levels of saliva and serum in ischemic heart disease. BMB Rep 41:55–61
Shigeyama C, Ansai T, Awano S, Soh I, Yoshida A, Hamasaki T, Kakinoki Y, Tominaga K, Takahashi T, Takehara T (2008) Salivary levels of cortisol and chromogranin A in patients with dry mouth compared with age-matched controls. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106:833–839. doi:10.1016/j.tripleo.2008.07.005
García PS, Alvarez JDP, Gutiérrez D, Cruz DA, Hernández CJJ (1989) Determination of insulin in saliva and its correlation with plasma insulin. Assessment of the possible participation of the salivary glands in the production of the hormone. Med Interna 6:5–9
Gungor S, Yücel G, Akinci A, Tabel Y, Ozerol IH, Yologlu S (2007) The role of ghrelin in weight gain and growth in epileptic children using valproate. J Child Neurol 22:1384–1388. doi:10.1177/0883073807307096
Aminoff MJ, Simon RP, Wiedemann E (1984) The hormonal responses to generalized tonic-clonic seizures. Brain 107:569–578. doi:10.1093/brain/107.2.569
Belton NR, Etheridge JE Jr, Millichap JG (1965) Effects of convulsions and anticonvulsants on blood sugar in rabbits. Epilepsia 6:243–249. doi:10.1111/j.1528-1157.1965.tb03792.x
Sanbar SS (1967) Metabolism of plasma glucose and lipids following diazoxide administration in dogs. Metabolism 16:259–270. doi:10.1016/0026-0495(67)90175-8
Levin SR, Booker J Jr, Smith DF, Grodsky GM (1970) Inhibition of insulin secretion by diphenylhydantoin in the isolated perfused pancreas. J Clin Endocrinol Metab 30:400–401
Beaumont NJ, Skinner VO, Tan TM, Ramesh BS, Byrne DJ, MacColl GS, Keen JN, Bouloux PM, Mikhailidis DP, Bruckdorfer KR, Vanderpump MP, Srai KS (2003) Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol Chem 278:8877–8880. doi:10.1074/jbc.C200575200
De Vriese C, Hacquebard M, Gregoire F, Carpentier Y, Delporte C (2007) Ghrelin interacts with human plasma lipoproteins. Endocrinology 148:2355–2362. doi:10.1210/en.2006-1281